Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909

Oct 02, 07:41 PM
Headliner
Share
Subscribe

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.

Share
Subscribe
Next
Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Key Findings of the NIAGARA and HIMALAYA Trials
by Pharmaceutical Executive